Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334776 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00334776: Completed Phase 2 study, sponsored by University of Southern California.
NCT00334776 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00334776, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.
Interventions
- BIOLOGICAL MART-1 antigen
- BIOLOGICAL gp100:209-217(210M) peptide vaccine
- BIOLOGICAL tyrosinase peptide
- BIOLOGICAL therapeutic autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00334776 record still lists
NCT00334776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which MART-1 antigen is the first listed.
NCT00334776 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00334776 about?
NCT00334776 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.
What is the current status of trial NCT00334776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2003-10. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00334776?
The interventions under investigation include: MART-1 antigen (BIOLOGICAL), gp100:209-217(210M) peptide vaccine (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL), therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00334776?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00334776's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia